HCPCS Code J9047: Injection, carfilzomib, 1 mg

Carfilzomib is a proteasome inhibitor for relapsed multiple myeloma and refractory multiple myeloma, typically as combination therapy to manage symptomatic disease, slow disease progression, and support responses such as stable disease.

Yes. Although it is a targeted proteasome inhibitor, payers treat it under chemotherapy administration rules for coding and reimbursement.

Report the drug with J9047 (per 1 mg) and pair it with appropriate chemotherapy administration codes (e.g., 96413/96415 for infusion or 96409/96411 for IV push), selected according to the documented intravenous infusion technique and session details.